These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 24355865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
    Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A.
    Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
    Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K.
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
    [Abstract] [Full Text] [Related]

  • 10. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [Abstract] [Full Text] [Related]

  • 11. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A.
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [Abstract] [Full Text] [Related]

  • 12. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 13. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
    Delgrange E, Daems T, Verhelst J, Abs R, Maiter D.
    Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
    De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
    Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A.
    J Clin Endocrinol Metab; 2013 Jan; 98(1):372-9. PubMed ID: 23162092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.